Physician profile
Mark A Cappel
NPI 1780668657
$4,434.52
in general payments reported to CMS, 2019-2025
27 companies · $375 in 2025
The $375 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $888 · 2020: $883 · 2021: $315 · 2022: $368 · 2023: $655 · 2024: $949 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,979.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $965.56 | 2019-2025 | |
| Janssen Biotech, INC. | $621.25 | 2019-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $318.60 | 2019-2024 | Dupixent, Libtayo |
| Janssen Scientific Affairs, LLC | $261.00 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $260.20 | 2023-2024 | Sotyktu |
| Ucb, INC. | $223.07 | 2019-2024 | Bimzelx |
| Leo Pharma INC. | $205.60 | 2019-2023 | Adbry |
| Stemline Therapeutics INC. | $197.13 | 2019-2020 | |
| Galderma Laboratories, L.P. | $195.30 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $171.39 | 2019-2025 | |
| Dermavant Sciences, INC. | $170.11 | 2023 | Vtama |
| Genzyme Corporation | $120.67 | 2019-2020 | |
| Lilly USA, LLC | $119.72 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $88.33 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $85.78 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $84.76 | 2019-2020 | |
| Dusa Pharmaceuticals, INC. | $70.41 | 2019 | |
| Celgene Corporation | $63.08 | 2019 | |
| Amgen INC. | $57.43 | 2020 | |
| Arcutis Biotherapeutics, INC. | $24.30 | 2024 | Zoryve |
| Verrica Pharmaceuticals INC. | $23.81 | 2024 | Ycanth |
| Solta Medical, A Division of Bausch Health US, LLC | $22.90 | 2025 | Clear+Brilliant |
| Kerecis Limited | $21.54 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Incyte Corporation | $18.39 | 2023 | Opzelura |
| Almirall LLC | $17.96 | 2020 | |
| Encore Dermatology INC. | $13.54 | 2020 | |
| Myriad Genetic Laboratories, INC. | $12.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Cappel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.